alive and kicking
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It's just my opinion and these side effects I never had in the past and I'm still having problems albeit not as bad as several weeks ago.
he blamed it all on MRNA side effects.......me too!
Up $18+ or >13% is my idea of a nice day.
Sure sounds like a scam to me.
My comment about managing money was about using it to get a product to market
Interestingly biotech CEOs who’ve come from WS, or other areas where they see a LOT of biotechs from 50k ft, seem to have a higher hit rate?
I_consider_all_five—(RVNC, ENTA, ABT, BMY, PFE)—to_be_buys at their current valuations, but there is a wide disparity in risk and upside potential:
ENTA, on the other hand, has a lot riding on clinical data yet to be reported. The other side of the coin is that, if ENTA’s COVID and RSV programs bear fruit, the upside is colossal.
Wow, that was some early price movement today.
Needham's Belanger noted the filler sales "significantly (outpaced) most Street estimates." He has a buy rating on RVNC stock and raised his price target to 38 from 35.
The excuse is that the placebo arm performed too well.
Likewise, the $2.73 billion market capitalization of RVNC stock is quite low and can easily soar 20 times if DAXXIFY become a blockbuster.
EOLS’ 1-pt data are not as good as RVNC’s:
Bavituximab new positive results of clinical trial
This trial has shown remarkable results ( if I read it correctly).
RVNC is finally moving up to where shareholders expected it to be following Daxxi approval. Hopefully this rise is just beginning but it is sure making me smile right now.
1,821 years without turning a profit! Only in biotech could that happen, LOL.
The stock is down 92% from its mid-202 IPO.
I think Novovax management would take 3 months to make a batch of soup from a can of Campbell’s (spoken as a bitter former shareholder).
Simplistically speaking, mRNA COVID vaccines and the NVAX COVID vaccine are similar in that that both introduce the spike protein into the body; while the mRNA vaccine does so by introducing mRNA into the body, where it is translated into spike protein, NVAX produces the spike protein in production using mRNA and then the spike protein is injected into patients.
oc631, since China is refusing free mRNA shots from the west, we will know if CCP is smarter than FDA.
Many fact checkers have brushed off the Africa experience, it will be hard to ignore 1 billion pts study.
I know many are holding out hope that combination flu and covid might be a sweet spot for NVAX. Unfortunately mRNA might also be better for flu bc they can wait longer to get the strains right before production.
Which vaccine was your 2nd dose?
As for me (old and fat):
3 PFE
1 MRNA
1 Bi-PFE
FYI cardiac symptoms is only one issue. The British cardiologist who used to back vaccine changed his mind because his dad died from cancer hyperprogression after getting vaxxed. Is it caused by T cell exhaustion? who knows?
Bbbwwwaaa hhhaaa! Hey radford, thanks for the laugh.
None of the patients needed to be admitted to hospital and all of these symptoms improved spontaneously. Using these five students as a positive outcome, the sensitivity and specificity of this screening method were 100% and 99.1%, respectively. Conclusion: Cardiac symptoms are common after the second dose of BNT162b2 vaccine, but the incidences of significant arrhythmias and myocarditis are only 0.1%.
Both virus and the mRNA create spike proteins in the infected. Every vax or natural infection add more harmful proteins that increase blood clots and risk of cardiac arrest. Why everyone is so eager to have spike proteins circulating in their blood is beyond me.
Conspiracy always buckle. Hard data won't. FDA reputation will be shredded to pieces by the damages done to the kids around the world.
None of the patients needed to be admitted to hospital and all of these symptoms improved spontaneously. Using these five students as a positive outcome, the sensitivity and specificity of this screening method were 100% and 99.1%, respectively. Conclusion: Cardiac symptoms are common after the second dose of BNT162b2 vaccine, but the incidences of significant arrhythmias and myocarditis are only 0.1%.
The point is, you didn't want unvaccinated people to be used in the EDP-235 trial because they might have been infected at some time in the past, but then you wanted a trial where ALL the participants had been vaccinated. That is absurd. If the trial were about efficacy then ideally you would want all unvaccinated people in the trial since they were most likely to suffer worse outcomes.
Bios like ENTA should be paid with tax $ to come up with antivirals.
I just don't trust this FDA anymore. Look at the way they treated NVAX, they probably will put up a few road blocks for ENTA. I am sure the former FDA commissioner will want to protect Pfizer's sales with all the strings he can pull.
I pray E-235 will stop transmission. Why ENTA is recruiting unvaxxed who might have developed natural immunity in the P2 only?
I wish ENTA would run another P2 to recruit any non-hospitalized adult with mild or moderate COVID-19 and symptom onset within 5 days who have been vaccinated > 3 months.
the way to make real money in biotech is to invest in companies with solid science and good management and then hold long term through all the bone-jarring volatility.
Discussion starts:
“2.5. Resistance
As with any other antiviral, resistance can be either basal or treatment-emergent.
Mutations in Mpro causing resistance to nirmatrelvir are already found in circulating SARS-CoV-2 viruses (Table 1 and Figure 1)…”
Hu et al identified in GISAID sequences 66 prevalent Mpro mutations located at the nirmatrelvir binding site, 11 of them (including S144M/F/A/G/Y, M165T, E166Q, H172Q/F, and Q192T/S/V) showing <10-fold change in enzymatic activity and resistance to nirmatrelvir (Ki > 10-fold increase) [53]. Sasi et al identified 5 mutations (N142L, E166M, Q189E, Q189I, and Q192T) that reduce the potency of nirmatrelvir: in particular, the IC50 of nirmatrelvir was reduced by 24-fold against E166M [54]. Dias Noske et al reported that N/R retained most of its in vitro activity against most of 14 naturally occurring polymorphism close to the binding site, with only G143S and Q189K linked to higher resistance.
In addition to in vitro data, nirmatrelvir can restrict viral infection in the respiratory organs of hamsters infected with BA.2 [41]. However, a pharmacokinetically human-equivalent dose of N/R did not significantly reduce shed SARS-CoV-2 titers in ferrets and failed to block virus transmission to untreated direct-contact ferrets, whereas transmission was fully suppressed in a group of animals treated with a human-equivalent dose of molnupiravir. Prophylactic administration of molnupiravir to uninfected ferrets in direct contact with infected animals blocked productive SARS-CoV-2 transmission, whereas all contacts treated with prophylactic N/R became infected[42].
It also doesn't hurt that in slide 21, in vitro cell culture data for live virus showed EDP-235 was more potent against omicron than either delta or alpha.
ENTA finally back over $50. First time since early October.
cheynew, what a misery that a super company like HALO goes down based on what analysts THINK HALO should achieve.
What a GREAT MINIPULATION TOOL if you can make the public believe that when a company does a super performance but less than what analysts projected it should go down.
Considering that Enanta owns the patent on Paxlovid, they should be able to make their own clinical trial supply if necessary.
Is the stock going to go up now?
RVNC is now up 13% after hours! After hours trading can be quite misleading and with the weekend upon us we will have a few days to find out if this rise is the real thing and the start of something big. Have a good weekend!
They wait until Friday after hours? Must think it’s bad news
• Slide 21 has new info about EDP-235’s live-virus potency against Omicron and other strains.
• Slide 22 has new preclinical EDP-235 info from a ferret model, including data on viral transmission from animal to animal.